BGB-B2033 + tislelizumab

**BGB-B2033 + tislelizumab** is an investigational combination therapy currently being evaluated in Phase 1 trials for advanced and metastatic solid tumors. BGB-B2033 is a novel bispecific monoclonal antibody targeting **4-1BB** (also known as TNFRSF9 or CD137) and **glypican-3 (GPC3)**, both of which are implicated in the regulation of immune cells and tumor cell proliferation. It is designed to activate immune cells (principally T cells) in the tumor microenvironment by engaging 4-1BB in a GPC3-dependent manner. Tislelizumab is a humanized IgG4 monoclonal antibody against **programmed death receptor 1 (PD-1)**, functioning as an immune checkpoint inhibitor to block immune suppression and enhance antitumor immune responses. The combination aims to synergistically promote robust immune-mediated tumor cell killing, particularly in cancers such as advanced hepatocellular carcinoma, AFP-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, and GPC3-positive squamous non-small cell lung cancer. The therapy is developed and sponsored by BeiGene, and both agents are administered intravenously in ongoing early-stage clinical studies[1][3][5][7][8][9][10].

Other names

BGB-B2033 + Tislelizumab